Nadofaragene firadenovec
- Generic Name
- Nadofaragene firadenovec
- Brand Names
- Adstiladrin
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1823059-12-6
- Unique Ingredient Identifier
- 0OOS09O1FH
- Background
Nadofaragene firadenovec (nadofaragene firadenovec-vncg) is a recombinant non-replicating adenovirus serotype 5 vector containing a transgene encoding human interferon alfa-2b (IFNα2b). It was approved by the FDA on December 2022 for the treatment of high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcino...
- Indication
Nadofaragene firadenovec is indicated for the treatment of adult patients with high-risk Bacillus CalmetteGuérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.
- Associated Conditions
- High risk BCG-unresponsive non-muscle invasive bladder cancer
- Associated Therapies
- -
Low-grade UTUC Treated with Nadofaragene Firadenovec Administered to Renal Pelvis
- Conditions
- Interventions
- First Posted Date
- 2024-10-31
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 20
- Registration Number
- NCT06668493
A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 150
- Registration Number
- NCT06545955
- Locations
- 🇺🇸
Ferring Investigational Site, Los Angeles, California, United States
Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-07-19
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 454
- Registration Number
- NCT06510374
- Locations
- 🇺🇸
Ferring Investigational Site, Virginia Beach, Virginia, United States
A Trial to Evaluate Efficacy of Reinduction With Nadofaragene Firadenovec in Subjects With CIS ± High-grade Ta/T1 and no Complete Response to First Nadofaragene Firadenovec Dose.
- First Posted Date
- 2024-04-30
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 25
- Registration Number
- NCT06390111
- Locations
- 🇺🇸
Ferring Investigational Site, Atlanta, Georgia, United States
ADSTILADRIN Early Utilization and Outcomes in the Real World Setting in the United States
- First Posted Date
- 2023-09-07
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 400
- Registration Number
- NCT06026332
- Locations
- 🇺🇸
Ferring Investigational Site, Virginia Beach, Virginia, United States
🇺🇸Ferring Investigation Site, Dallas, Texas, United States
Efficacy & Safety of RAd-IFN Administered with Celecoxib & Gemcitabine in Patients with Malignant Pleural Mesothelioma
- Conditions
- Interventions
- First Posted Date
- 2018-10-18
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Ferring Ventures Limited
- Target Recruit Count
- 53
- Registration Number
- NCT03710876
- Locations
- 🇺🇸
University of California, Los Angeles (UCLA) - Medical Center, Los Angeles, California, United States
🇺🇸University of California, San Francisco (UCSF), San Francisco, California, United States
🇺🇸H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder Cancer
- First Posted Date
- 2012-09-18
- Last Posted Date
- 2017-07-24
- Lead Sponsor
- FKD Therapies Oy
- Target Recruit Count
- 40
- Registration Number
- NCT01687244
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.